**ASX Announcement**

**ASX : ENP**

12 November 2026

# Results of Annual General Meeting

**Melbourne, Australia –** Entropy Neurodynamics Limited ('**Entropy**' or the '**Company**') (**ASX: ENP**), a clinical-stage biotechnology company advises that its Annual General Meeting was held today at 4:00pm (AEDT).

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are included in the attached document. All resolutions were carried by the requisite majorities.

This announcement has been authorised by the Board of Entropy Neurodynamics Limited.

– ENDS –

## INVESTOR & MEDIA CONTACT


**Jason Carroll**
Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@tryptherapeutics.com

**Henry Jordan**
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au


## About Entropy Neurodynamics Limited

*Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials provided encouraging evidence of the potential clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.*

## Register for updates

*The Company encourages investors to register their details with the Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done via the following steps:*

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password.*
- *If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding*

*Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.*

- *Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and selecting 'electronic only'.*

## Risks associated with Psilocin

*All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include a temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.*

## Forward-Looking Information

*Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.*

# Results of Meeting

## Entropy Neurodynamics Limited

Annual General Meeting

Thursday, 12 November 2026

**Automic**
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| | | Proxy Votes (as at proxy voting close) | | | | Poll Results (if applicable) | | | Results |
|---|---|---|---|---|---|---|---|---|---|
| **Resolution** | **Decided by Show of Hands (S) or Poll (P)** | **FOR** | **AGAINST** | **ABSTAIN** | **PROXY'S DISCRETION** | **FOR** | **AGAINST** | **ABSTAIN** | **OUTCOME** |
| 1 NON-BINDING RESOLUTION TO ADOPT REMUNERATION REPORT | P | 36,331,001<br>98.90% | 86,335<br>0.24% | 725,334 | 318,000<br>0.87% | 36,649,001<br>99.76% | 86,335<br>0.24% | 725,334 | Carried |
| 2 RE-ELECTION OF MR CHRIS NTOUMENOPOULOS AS A DIRECTOR | P | 176,029,932<br>98.98% | 1,348,342<br>0.76% | 19,791,176 | 461,164<br>0.26% | 201,824,615<br>99.34% | 1,348,342<br>0.66% | 19,791,176 | Carried |
| 3 APPROVAL OF 10% PLACEMENT FACILITY | P | 195,953,115<br>99.47% | 589,335<br>0.30% | 627,000 | 461,164<br>0.23% | 221,747,798<br>99.73% | 589,335<br>0.27% | 627,000 | Carried |
| 4 APPROVAL FOR ISSUE OF OPTIONS TO MR JASON CARROLL | P | 35,653,966<br>95.50% | 1,218,540<br>3.26% | 127,000 | 461,164<br>1.24% | 36,115,130<br>96.74% | 1,218,540<br>3.26% | 127,000 | Carried |
| 5 APPROVAL FOR ISSUE OF OPTIONS TO MR HERWIG JANSSEN | P | 36,253,966<br>97.11% | 618,540<br>1.66% | 127,000 | 461,164<br>1.24% | 36,715,130<br>98.34% | 618,540<br>1.66% | 127,000 | Carried |
| 6 APPROVAL FOR ISSUE OF OPTIONS TO MR JASON CARROLL | P | 35,653,966<br>95.50% | 1,218,540<br>3.26% | 127,000 | 461,164<br>1.24% | 36,115,130<br>96.74% | 1,218,540<br>3.26% | 127,000 | Carried |
| 7 APPROVAL FOR ISSUE OF OPTIONS TO MR CHRIS NTOUMENOPOULOS | P | 34,388,966<br>92.11% | 2,483,540<br>6.65% | 127,000 | 461,164<br>1.24% | 34,850,130<br>93.35% | 2,483,540<br>6.65% | 127,000 | Carried |
| 8 APPROVAL FOR ISSUE OF OPTIONS TO MR GAGE JULL | P | 34,388,966<br>92.11% | 1,218,540<br>3.26% | 127,000 | 1,726,164<br>4.62% | 36,115,130<br>96.74% | 1,218,540<br>3.26% | 127,000 | Carried |
| 9 APPROVAL FOR ISSUE OF OPTIONS TO DR DANIEL TILLETT | P | 34,388,966<br>92.11% | 2,483,540<br>6.65% | 127,000 | 461,164<br>1.24% | 34,850,130<br>93.35% | 2,483,540<br>6.65% | 127,000 | Carried |

| | | Proxy Votes (as at proxy voting close) | | | | Poll Results (if applicable) | | | Results |
|---|---|---|---|---|---|---|---|---|---|
| **Resolution** | **Decided by Show of Hands (S) or Poll (P)** | **FOR** | **AGAINST** | **ABSTAIN** | **PROXY'S DISCRETION** | **FOR** | **AGAINST** | **ABSTAIN** | **OUTCOME** |
| 10 MODIFICATION OF EXISTING CONSTITUTION | P | 194,447,383<br>98.84% | 542,993<br>0.28% | 902,074 | 1,738,164<br>0.88% | 221,519,066<br>99.76% | 542,993<br>0.24% | 902,074 | Carried |